BridgeBio Pharma (NasdaqGS:BBIO) FY Conference Transcript

Summary of BridgeBio Pharma FY Conference Call Company Overview - Company: BridgeBio Pharma (NasdaqGS:BBIO) - Event: 44th Annual J.P. Morgan Healthcare Conference - Date: January 12, 2026 - CEO: Neil Kumar Key Points Company Milestones - BridgeBio celebrates its 10th anniversary, having developed a highly efficient R&D engine for genetic diseases with three approved products and three more expected in the next 12 months [2][3] - Nearly 20 Investigational New Drug (IND) applications generated, impacting approximately 10,000 patient lives [3] Financial Performance - Q4 revenue pre-announced at $146 million, representing a 35% growth from the previous quarter and suggesting a 60% compound annual growth rate (CAGR) [4] - Total revenue for the first four quarters reached $362 million [5] - The company aims for a 30%-35% peak year market share by volume for its product Attruby, with over 25% market share achieved in the first year [5] Product Updates ATTR Cardiomyopathy - Attruby is the first and only near-complete stabilizer approved by the FDA, showing a 42% relative risk reduction in all-cause mortality and cardiovascular hospitalization at 30 months [6] - Over 50 publications and abstracts have been released regarding the drug's efficacy and patient population performance [6] Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) - Interim phase three results showed a 1.8 times increase in glycosylation of the alpha-dystroglycan complex and an 82% decrease in muscle damage [15] - Statistically significant improvements in ambulation and breathing were observed, indicating potential therapeutic cures for some patients [16] ADH1 - Phase 3 results indicated a 76% responder rate for normalization of urine and serum calcium levels, significantly outperforming the standard of care [20] - The company has identified 1,700 unique patients with ADH1 through improved genetic testing and updated guidelines [24] Chronic Hypoparathyroidism - A trial showed 80% normalization of urine and serum calcium levels, with plans to initiate the Reclaim HP trial mid-year [26] Achondroplasia and Hypochondroplasia - The company is advancing its small molecule program targeting FGFR3 over-activation, with phase three data expected in Q1 [28][29] Canavan Disease - A gene therapy approach is being developed, with a BLA filing anticipated in 2027 [36] Market Strategy - The company employs a decentralized model for product launches, leveraging existing infrastructure to minimize costs [37] - Market research indicates a potential 52% market share for its new products based on favorable profiles compared to existing treatments [34] Future Outlook - BridgeBio emphasizes that it is still "day one" in the era of genetic medicine, with ongoing advancements in genetic research and therapeutic development [38][39] - The company is focused on identifying new patient populations and expanding its pipeline, with 17 early-stage programs in development at Gondola Bio [40] Conclusion - BridgeBio is well-financed and positioned for significant growth, aiming to serve more patients with innovative therapies in the coming years [48]